QAS.AI is focused on optimizing endovascular treatments of neurovascular conditions by providing artificial intelligence driven intra-operative guidance to clinicians. The algorithms use angiographic imaging that is routinely acquired during an endovascular procedure and provides feedback regarding the future success or failure rate within 250 milliseconds. This allows clinicians to gain confidence in their treatment or reassess and adjust the treatment while the patient is still on the operating table. Currently, the algorithms can predict the future 6-month occlusion outcome of endovascularly treated intracranial aneurysms, and can detect the level of tissue perfusion of a patient undergoing mechanical thrombectomy for a large vessel occlusion ischemic stroke.The mission of the company is driven by the needs of neuro-surgeons and -interventionalists worldwide. QAS.AI has been backed by world renowned clinicians at University at Buffalo Neurosurgery (UBNS), and University of South Florida. In employment to further the technology and bring these algorithms to the clinic are respected MDs and PhDs in the field of Neurosurgery, Medical Physics, Biomedical Engineering, Artificial Intelligence, Biophysics and Pathology.QAS.AI has been recognized as a promising small business and awarded funding by the National Science Foundation in the form of Small Business Technology Transfer (STTR) and Innovation Corps (I-Corps) grants. It has also been supported by the University at Buffalo and the headquarters currently reside in a startup incubator at the Center of Excellence in Bioinformatics and Life Sciences (CBLS).